ID   WM164
AC   CVCL_7928
SY   WM-164; WM 164
DR   cancercelllines; CVCL_7928
DR   Cell_Model_Passport; SIDM00802
DR   ChEMBL-Cells; CHEMBL4630601
DR   ChEMBL-Targets; CHEMBL4630701
DR   Cosmic; 888857
DR   Cosmic; 897481
DR   Cosmic; 928684
DR   Cosmic; 1155550
DR   Cosmic; 1187586
DR   Cosmic; 1303065
DR   GEO; GSM109030
DR   GEO; GSM186471
DR   GEO; GSM186472
DR   GEO; GSM952584
DR   PRIDE; PXD004343
DR   Progenetix; CVCL_7928
DR   PubChem_Cell_line; CVCL_7928
DR   Rockland; WM164-01-0001
DR   Wikidata; Q54994187
RX   PubMed=2156614;
RX   PubMed=2253310;
RX   PubMed=2918552;
RX   PubMed=8342600;
RX   PubMed=15009714;
RX   PubMed=16827748;
RX   PubMed=18632627;
RX   PubMed=18790768;
RX   PubMed=30380804;
RX   PubMed=34206371;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Population: Caucasian.
CC   Doubling time: 48 hours (PubMed=2253310).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=15009714; PubMed=18632627; Wistar).
CC   Omics: Deep proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: CSF1PO: 11,12->12, D18S51: 12,21->10,12,13, D2S1338: 19->18,19, D5S818: 11,12->12, FGA: 20->21,25 and vWA: 14,15->14,18.
CC   Derived from site: Metastatic; Arm, skin; UBERON=UBERON_0002427.
ST   Source(s): Wistar
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 13
ST   D18S51: 10,12,13
ST   D19S433: 13
ST   D21S11: 28,31.2
ST   D2S1338: 18,19
ST   D3S1358: 18
ST   D5S818: 12
ST   D7S820: 9,10
ST   D8S1179: 13,14
ST   FGA: 21,25
ST   TH01: 9
ST   TPOX: 8,10
ST   vWA: 14,18
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_DG51 ! Mel1617
SX   Male
AG   22Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   PubMed=2156614;
RA   Herlyn D., Iliopoulos D., Jensen P.J., Parmiter A.H., Baird J.,
RA   Hotta H., Adachi K., Ross A.H., Jambrosic J.A., Koprowski H., Herlyn M.;
RT   "In vitro properties of human melanoma cells metastatic in nude
RT   mice.";
RL   Cancer Res. 50:2296-2302(1990).
//
RX   PubMed=2253310; DOI=10.1007/BF00046337;
RA   Herlyn M.;
RT   "Human melanoma: development and progression.";
RL   Cancer Metastasis Rev. 9:101-112(1990).
//
RX   PubMed=2918552; DOI=10.1093/jnci/81.6.440;
RA   Iliopoulos D., Ernst C.S., Steplewski Z., Jambrosic J.A., Rodeck U.,
RA   Herlyn M., Clark W.H. Jr., Koprowski H., Herlyn D.;
RT   "Inhibition of metastases of a human melanoma xenograft by monoclonal
RT   antibody to the GD2/GD3 gangliosides.";
RL   J. Natl. Cancer Inst. 81:440-444(1989).
//
RX   PubMed=8342600;
RA   Juhasz I., Albelda S.M., Elder D.E., Murphy G.F., Adachi K.,
RA   Herlyn D., Valyi-Nagy I.T., Herlyn M.;
RT   "Growth and invasion of human melanomas in human skin grafted to
RT   immunodeficient mice.";
RL   Am. J. Pathol. 143:528-537(1993).
//
RX   PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x;
RA   Tsao H., Goel V., Wu H., Yang G., Haluska F.G.;
RT   "Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1
RT   inactivation in melanoma.";
RL   J. Invest. Dermatol. 122:337-341(2004).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=18790768; DOI=10.1158/1535-7163.MCT-08-0431;
RA   Smalley K.S.M., Lioni M., Dalla Palma M., Xiao M., Desai B.,
RA   Egyhazi Brage S., Hansson J., Wu H., King A.J., Van Belle P.,
RA   Elder D.E., Flaherty K.T., Herlyn M., Nathanson K.L.;
RT   "Increased cyclin D1 expression can mediate BRAF inhibitor resistance
RT   in BRAF V600E-mutated melanomas.";
RL   Mol. Cancer Ther. 7:2876-2883(2008).
//
RX   PubMed=30380804; DOI=10.3390/molecules23112823;
RA   Kretschmer N., Deutsch A.J.A., Durchschein C., Rinner B., Stallinger A.,
RA   Higareda-Almaraz J.C., Scheideler M., Lohberger B., Bauer R.;
RT   "Comparative gene expression analysis in WM164 melanoma cells revealed
RT   that beta-beta-dimethylacrylshikonin leads to ROS generation, loss of
RT   mitochondrial membrane potential, and autophagy induction.";
RL   Molecules 23:2823.1-2823.17(2018).
//
RX   PubMed=34206371; DOI=10.3390/cancers13133111;
RA   Podgorska E., Kim T.-K., Janjetovic Z., Urbanska K., Tuckey R.C.,
RA   Bae S., Slominski A.T.;
RT   "Knocking out the vitamin D receptor enhances malignancy and decreases
RT   responsiveness to vitamin D3 hydroxyderivatives in human melanoma
RT   cells.";
RL   Cancers (Basel) 13:3111.1-3111.15(2021).
//